FDA approves Pfizer-BioNTech LP.8.1-adapted monovalent COVID-19 vaccine for high-risk groups EP News Bureau Aug 28, 2025 The vaccine is approved for adults aged 65 years and older and individuals aged 5 to 64 years with underlying conditions
